Drug
XR-NTX
XR-NTX is a pharmaceutical drug with 6 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
2(33%)
Results Posted
50%(2 trials)
Phase Distribution
Ph phase_2
3
50%
Ph phase_3
2
33%
Ph phase_4
1
17%
Phase Distribution
0
Early Stage
3
Mid Stage
3
Late Stage
Phase Distribution6 total trials
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
2(33.3%)
Phase 4Post-market surveillance
1(16.7%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
6
all time
Status Distribution
Active(2)
Completed(4)
Detailed Status
Completed4
Active, not recruiting2
Development Timeline
Analytics
Development Status
Total Trials
6
Active
2
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 23 (50.0%)
Phase 32 (33.3%)
Phase 41 (16.7%)
Trials by Status
completed467%
active_not_recruiting233%
Recent Activity
2 active trials
Showing 5 of 6
active_not_recruitingphase_2
Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail
NCT04408313
completedphase_3
Long-acting Naltrexone for Pre-release Prisoners
NCT02867124
active_not_recruitingphase_2
Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
NCT04464980
completedphase_4
Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults
NCT04219540
completedphase_2
Harm Reduction With Pharmacotherapy (HaRP)
NCT01932801
Clinical Trials (6)
Showing 6 of 6 trials
NCT04408313Phase 2
Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail
NCT02867124Phase 3
Long-acting Naltrexone for Pre-release Prisoners
NCT04464980Phase 2
Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
NCT04219540Phase 4
Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults
NCT01932801Phase 2
Harm Reduction With Pharmacotherapy (HaRP)
NCT02110264Phase 3
Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6